Bath Savings Trust Co Sells 32,577 Shares of Edwards Lifesciences Co. (NYSE:EW)

Bath Savings Trust Co lowered its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 62.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,977 shares of the medical research company's stock after selling 32,577 shares during the period. Bath Savings Trust Co's holdings in Edwards Lifesciences were worth $1,479,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its position in Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company's stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Edwards Lifesciences by 239.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company's stock valued at $243,745,000 after buying an additional 2,606,950 shares during the period. Nordea Investment Management AB boosted its stake in Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock valued at $301,355,000 after buying an additional 1,043,484 shares in the last quarter. Fisher Asset Management LLC grew its holdings in Edwards Lifesciences by 9.8% during the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company's stock worth $599,078,000 after acquiring an additional 806,705 shares during the period. Finally, Worldquant Millennium Advisors LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at about $39,628,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Stock Up 0.3 %

Shares of EW traded up $0.22 during mid-day trading on Tuesday, hitting $73.76. 3,093,938 shares of the company's stock were exchanged, compared to its average volume of 4,185,385. The firm has a fifty day moving average of $71.18 and a two-hundred day moving average of $72.41. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The stock has a market cap of $43.50 billion, a price-to-earnings ratio of 10.64, a P/E/G ratio of 3.63 and a beta of 1.11. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the prior year, the business posted $0.59 EPS. Edwards Lifesciences's quarterly revenue was up 8.9% on a year-over-year basis. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on EW shares. Bank of America raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Robert W. Baird dropped their price target on Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating on the stock in a report on Friday, October 25th. Jefferies Financial Group lowered Edwards Lifesciences from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $85.00 to $70.00 in a research note on Wednesday, September 18th. Daiwa America lowered Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 30th. Finally, Sanford C. Bernstein upgraded Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a research report on Monday, October 28th. Sixteen investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $79.40.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the firm's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm's stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 37,500 shares of company stock worth $2,508,350. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.